FDA Clearance Tracker · P860022-S053
BOSTON EQUALENS/BOSTON EQUALENS II
Last checked: Nov 20, 2026Latest source record: Nov 21, 2001 (this decision)Source: openFDAMethods & limitations
Decided
Nov 21, 2001
Approved
Time to decision
57 days
Received Sep 25, 2001. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track
Device class
Class III
The decision
- FDA number
- P860022-S053
- Device name
- BOSTON EQUALENS/BOSTON EQUALENS II
- Applicant
- Bausch & Lomb
- Applicant location
- Rochester, NY
- Received
- Sep 25, 2001
- Decided
- Nov 21, 2001
- Decision
- Approved
- Supplement type
- Normal 180 Day Track
- Reason for supplement
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
- Original approval
- P860022
Device type
- Device class
- Class III
- Regulation
- 21 CFR 886.5916
- Specialty
- Ophthalmology
FDA's approval statement
As written in FDA's record.
APPROVAL FOR WET SHIPPING AND UP TO 30 DAYS STORAGE IN BOSTON ADVANCE COMFORT FORMULA CONDITIONING SOLUTION.
Source documents
Other decisions for Bausch & Lomb
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
- Bausch + Lomb Multifocal for Astigmatism (kalifilcon A) One-Day Soft (hydrophilic) Contact Lens510(k)
K262941 · Decided Oct 16, 2026 · 56 days after receipt
Device type: Lenses, Soft Contact, Daily Wear (LPL) · Ophthalmology
7 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.